Improved health status with SGLT2-inhibitor in HFrEF

3' education - Nov. 25, 2019 - Prof. Mikhail Kosiborod - Kansas City, MO, USA - AHA 2019, Philadelphia

Educational information

This video was recorded at the AHA in Philadelphia, USA, on november 17, 2019.

Faculty

Dr. Mikhail Kosiborod is a cardiologist, Vice President of Research at Saint Luke’s Health System, Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardio Metabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.